Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes.
about
Serum ferritin: Past, present and futureFerritin for the clinicianAdult-onset Still's disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine AMacrophage activation syndrome in a child with systemic juvenile rheumatoid arthritisReactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature.Profile of hemophagocytic lymphohistiocytosis in children in a tertiary care hospital in India.Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients.An Unusual Case of Adult-Onset Still's Disease with Hemophagocytic Syndrome, Necrotic Leukoencephalopathy and Disseminated Intravascular Coagulation.Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patientsIntravenous immunoglobulin as clinical immune-modulating therapy.Scrub typhus associated with hemophagocytic lymphohistiocytosis: A report of six pediatric patients.Treatment of adult-onset Still's disease: a reviewThe hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndromeIVIG--mechanisms of action.Modern management of children with haemophagocytic lymphohistiocytosis.Hodgkin's lymphoma, Epstein-Barr virus reactivation and fatal haemophagocytic syndrome.Macrophage activation syndrome and other systemic inflammatory conditions after BMT.Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease.Secondary haemophagocytic lymphohistiocytosis: Experience from the Uppsala University HospitalHemophagocytic Lymphohistiocytosis Associated with Visceral Leishmaniasis: Varied PresentationDisruption of Endothelial Cell Homeostasis Plays a Key Role in the Early Pathogenesis of Coronary Artery Abnormalities in Kawasaki Disease.Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review.Severe hemophagocytic lymphohistiocytosis in adults-experience from an intensive care unit from North India.Human pooled immunoglobulin in the treatment of chronic pain syndromes.Hemophagocytic lymphohistiocytosis: an unusual complication of leprosy.Conditions associated with extreme hyperferritinaemia (>3000 μg/L) in adults.Very low density lipoprotein, chylomicron, and lipoprotein (a) are more useful to detect the development of macrophage activation syndrome in adult-onset still's disease as compared with cytokines and triglyceride.Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.The influence of various therapeutic regimens on early clinical and laboratory response and outcome of children with secondary hemophagocytic lymphohistiocytosis.Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus.
P2860
Q24626621-7B9B6E2E-4EDD-4027-BF44-2865D7F7A7CBQ24642942-A6E49EDF-C0FA-4E74-B950-EAC8094DA317Q28167268-7C08AA6C-CA6F-4209-9160-77A0BF553FF6Q28187372-85E5E0F6-4CCD-4BEE-93FA-AC4F074E236EQ33370577-F9A75160-B501-4FDD-8713-885963EB7BB7Q33392440-B6ACE43A-D3C0-4F9B-85DF-0FF58EB7E302Q33414045-5B5F05C5-4DFA-47FB-B78A-A197DA09D589Q33414465-2569F008-076B-4115-A99F-BE8D2EFC2E80Q33420069-1C9A01B8-DF96-46B6-82A4-ACE04DD0FFE0Q33420267-33C8E60A-062E-4A56-B427-7DF6B44C4E30Q33435741-A259089E-4EB5-4AAB-8A4D-F43FE16B259BQ34043097-2AEE68CF-EF4B-43CF-BC02-8ECADBCA5CCCQ34966670-D7EF37AF-5985-4385-9A75-37D42B308FB6Q35161081-35E2FBDE-69C8-47BB-877D-7FFB34A0122DQ35607712-A8E810E1-DC11-4AA1-B34E-D5DE2EA95540Q35640337-ACFE61DD-940A-448A-9CC0-28D10C7ACC2AQ36406434-905079E2-DAC2-4252-9026-25CE37B59EC0Q36521192-1172DBC7-19D2-419A-A31D-254CC625F50BQ36754263-0FF4B3C8-F1EC-4A77-928D-4E52E01087F3Q37048394-2D25876F-FA53-4F12-AA00-115361454F09Q37678347-9EED4DFA-D45A-4936-B99E-608A557745E2Q37993678-EA110057-778B-4A67-A898-16D515E483F9Q38088660-D484AC34-6F60-4223-BFC6-B6530DEB5E91Q38096360-E28645DF-4DCE-4CBD-BE22-C941970E1013Q39381451-9D4D01E7-2261-4B30-9079-C30EDF206787Q39422053-9BD01EC6-1ECA-4D10-ADF3-903F7848B032Q41103710-F6F9A7B8-B53C-49B5-9BC8-FA3442FA3C04Q45994732-B101E549-9C5F-4E3A-B4A0-F0D34C5EB0D7Q47931407-3BC2767D-949A-47AE-9C26-E3932066595CQ49592363-47B2A4A4-602E-4776-B5E8-1C66341AF875Q49942692-F4503877-3E26-4FF7-8D67-CBD137E73C4C
P2860
Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Hyperferritinemia as indicator ...... crophage activation syndromes.
@en
Hyperferritinemia as indicator ...... crophage activation syndromes.
@nl
type
label
Hyperferritinemia as indicator ...... crophage activation syndromes.
@en
Hyperferritinemia as indicator ...... crophage activation syndromes.
@nl
prefLabel
Hyperferritinemia as indicator ...... crophage activation syndromes.
@en
Hyperferritinemia as indicator ...... crophage activation syndromes.
@nl
P2093
P2860
P356
P1476
Hyperferritinemia as indicator ...... crophage activation syndromes.
@en
P2093
Cottagnoud P
Emmenegger U
P2860
P356
10.1002/AJH.1141
P577
2001-09-01T00:00:00Z